Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Review

    Tapinarof: A Felicitous Discovery in Psoriasis Treatment

    Indumathi Prabath1, Subhiksha Subramanian1★, Jamuna Rani1★ Corresponding author

    1. 1Department of Pharmacology, SRM Medical College Hospital & Research Centre, Kattankulathur, Tamil Nadu, India.

    CORRESPONDENCE

    Subhiksha Subramanian

    Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chengalpattu, Tamil Nādu 603211, India.

    subhikss@srmist.edu.in

    Received: 27-07-2022; Revised: 03-09-2022; Accepted: 07-09-2022.

    Volume 13, Issue 3 · pp. 222–228 · PUBLISHED 2022 · DOI: 10.1177/0976500X221130851

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Tapinarof is a novel topical formulation approved recently, in May 2022, by the United States Food and Drug Administration to treat plaque psoriasis. Existing topical therapies for psoriasis are limited by systemic and local adverse effects, medication cost and repeated administration, thus significantly hampering the compliance of patients to therapy. These limitations can be resolved by tapinarof owing to its better efficacy and favourable safety profile in psoriasis management. Tapinarof was developed with a unique mechanism targeting the aryl hydrocarbon receptor (AhR) involved in inflammation and modulation of skin barrier integrity in inflammatory dermatological disorders such as psoriasis and atopic dermatitis. The efficacy and safety outcomes of tapinarof in psoriasis were justified through the two pivotal clinical trials, namely, PSOARING 1 and PSOARING 2. The common adverse effects observed with tapinarof are folliculitis, contact dermatitis and headache. The literature search was conducted for efficacy and safety of tapinarof in the electronic databases of PubMed and Cochrane using a combination of keywords such as tapinarof, psoriasis and AhR. This review will delineate the molecular mechanisms underlying the action of tapinarof and also summarise the trial data supporting the claim that tapinarof is replacing the existing standard of care in psoriasis management.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Prabath, I., Subramanian, S., & Rani, J. (2022). Tapinarof: A Felicitous Discovery in Psoriasis Treatment. Journal of Pharmacology and Pharmacotherapeutics, 13(3), 222–228. https://doi.org/10.1177/0976500X221130851